Randox Licenses Seegene Technology | GenomeWeb

NEW YORK (GenomeWeb News) – Randox Laboratories has agreed to a non-exclusive license for Seegene's technology for use with its biochip array platform, Seegene said today.

The agreement will give Randox access to Seegene's Dual Priming Oligo technology, which it will use to develop high-throughput diagnostic screening panels to detect a variety of pathogens that cause either respiratory or sexually transmitted diseases from one sample.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.